These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 3542452)

  • 1. Assessing effect of mixing insulins by glucose-clamp technique in subjects with diabetes mellitus.
    Colagiuri S; Villalobos S
    Diabetes Care; 1986; 9(6):579-86. PubMed ID: 3542452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Miscibility of human semisynthetic regular and lente insulin and human biosynthetic regular and NPH insulin.
    Olsson PO; Hans A; Henning VS
    Diabetes Care; 1987; 10(4):473-7. PubMed ID: 3304898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical effects of mixing short- and intermediate-acting insulins in the treatment of non-insulin-dependent diabetes.
    Best JD; Ley CJ; Strauss BJ; Alford FP; Aitken PM
    Med J Aust; 1987 Jun; 146(12):621-3, 627. PubMed ID: 3306298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mixtures of human intermediate and human regular insulin in type 1 diabetic patients. Evaluation of free insulin levels and insulin action on glucose metabolism after combined and separate subcutaneous administration.
    Klauser R; Schernthaner G; Prager R
    Diabetes Res Clin Pract; 1988 Sep; 5(3):185-90. PubMed ID: 3065016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The contribution of intermediate-acting insulin preparations to daytime insulin treatment.
    Robert JJ; Chevenne D; Debray M
    Diabet Med; 1989 Aug; 6(6):531-6. PubMed ID: 2527136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced solubility of short-acting soluble insulins when mixed with longer-acting insulins.
    Nolte MS; Poon V; Grodsky GM; Forsham PH; Karam JH
    Diabetes; 1983 Dec; 32(12):1177-81. PubMed ID: 6360762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of mixing short- and intermediate-acting insulins on absorption course and biologic effect of short-acting preparation.
    Forlani G; Santacroce G; Ciavarella A; Capelli M; Mattioli L; Vannini P
    Diabetes Care; 1986; 9(6):587-90. PubMed ID: 3542453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mixing short and intermediate acting insulins in the syringe: effect on postprandial blood glucose concentrations in type I diabetics.
    Heine RJ; Bilo HJ; Sikkenk AC; van der Veen EA
    Br Med J (Clin Res Ed); 1985 Jan; 290(6463):204-5. PubMed ID: 3917752
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
    Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
    Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the anatomical region used for insulin injections on glycemia in type I diabetes subjects.
    Bantle JP; Neal L; Frankamp LM
    Diabetes Care; 1993 Dec; 16(12):1592-7. PubMed ID: 8299455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures.
    Roach P; Woodworth JR
    Clin Pharmacokinet; 2002; 41(13):1043-57. PubMed ID: 12403642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed onset of action of soluble insulin after premixing with U100 lente insulin.
    Heine RJ; Sikkenk AC; Eizenga WH; van der Veen EA
    Diabetes Res Clin Pract; 1986; 2(6):353-8. PubMed ID: 3545725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mixing insulins in 1990.
    Anderson JH; Campbell RK
    Diabetes Educ; 1990; 16(5):380-7. PubMed ID: 2202572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absorption kinetics and action profiles of mixtures of short- and intermediate-acting insulins.
    Heine RJ; Bilo HJ; Fonk T; van der Veen EA; van der Meer J
    Diabetologia; 1984 Dec; 27(6):558-62. PubMed ID: 6397384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-dependent subcutaneous absorption of porcine, bovine and human NPH insulins.
    Hildebrandt P; Birch K; Sestoft L; Vølund A
    Acta Med Scand; 1984; 215(1):69-73. PubMed ID: 6364700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of injection techniques for soluble and protamine zinc insulins in diabetes mellitus.
    Harrower AD; Duncan LJ; Clarke BF
    Practitioner; 1975 Feb; 214(1280):228-31. PubMed ID: 1144249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of mixing human soluble and human crystalline zinc-suspension insulin: plasma insulin and blood glucose profiles after subcutaneous injection.
    Francis AJ; Hanning I; Alberti KG
    Diabet Med; 1985 May; 2(3):177-80. PubMed ID: 2952414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different daily blood glucose control and free insulin levels during treatment with mixtures of soluble and lente or soluble and NPH semisynthetic human insulins.
    Cucinotta D; Di Benedetto A; Gigante A; Di Cesare E; Musolino C; Squadrito G
    Diabete Metab; 1989; 15(4):182-7. PubMed ID: 2680669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Premixed insulin at ratio 3/7 and regular + isophane insulins at mixing ratios from 2/8 to 4/6 achieve the same metabolic control.
    Cucinotta D; Mannino D; Lasco A; Di Cesare E; Musolino C; Alessi R
    Diabete Metab; 1991; 17(1):49-54. PubMed ID: 1868960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetics and metabolic activity of biosynthetic NPH insulin evaluated by the glucose clamp technique.
    Massi Benedetti M; Bueti A; Mannino D; Bellomo G; Antonella MA; Calabrese G; Zega G; Brunetti P
    Diabetes Care; 1984; 7(2):132-6. PubMed ID: 6376009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.